Regenxbio Inc. (RGNX)
Nasdaq: RGNX · Biological Products, (No Diagnostic Substances) · Rockville, MD · filing with the SEC since 2013
Who owns Regenxbio Inc.
As filed with the SECHolders of 5% or more
4
Redmile Group, LLC holds 9.9% of Common Stock, par value $0.0001 per share, as its SCHEDULE 13G/A filed Aug 14, 2025 says.
Directors and officers
15
report now, of 23 people on the record since 2015. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 4 named at left.
Holders of 5% or moreshare of the class, as filed
Redmile Group, LLC
SCHEDULE 13G/A · filed Aug 14, 2025 · Common Stock, par value $0.0001 per share
Blackrock, Inc.
SCHEDULE 13G/A · filed Apr 24, 2025 · Common Stock · 11% in Jan 8, 2025
JPMorgan Chase & Co.
SCHEDULE 13G · filed Oct 13, 2026 · Common Stock, par value $0.0001 per share · 4.4% in Jun 4, 2026
State Street Corporation
SCHEDULE 13G · filed May 12, 2026 · COMMON STOCK · 4.4% in Feb 5, 2025
BlackRock Portfolio Management LLC
SCHEDULE 13G/A · filed Jan 21, 2026 · Common Stock · reported falling below 5%, from 6.2% in Jul 15, 2025
The Vanguard Group
SCHEDULE 13G/A · filed Mar 27, 2026 · Common Stock · reported falling below 5%, from 6.02% in Jan 31, 2025
What RGNX reports owning in othersstakes of 5% or more, and other ties
Other ties the annual report names
Uni Qure N V
A company bought · acquisition · owns, named in the 10-K filed Mar 5, 2026
2 subsidiaries in 2 countries, from the list filed with the 10-K filed Mar 5, 2026.
Insider tradesForm 4
5sales
2purchases
3sales on a scheduled plan
1people selling
$900,000sold, in dollars
$900,000bought, in dollars
Open-market trades on Form 4 from Nov 3, 2025 to Nov 3, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Nov 3, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window2 of 24 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Pakola Steve | Chief Medical Officer | 5 | $900,000 | 3 | 0 | $0 |
| Ciongoli Gregory Austin | director | 0 | $0 | 0 | 2 | $900,000 |